Gilead Sciences, Inc. has partnered with Compugen Ltd. on the development and commercialization of a preclinical asset that could be a new kind of cancer immunotherapy. Gilead agreed to pay $60m up front for rights to Compugen’s COM503, which is a potential first-in-class antibody that blocks the interaction between IL-18 binding protein and IL-18, releasing natural IL-18 in the tumor microenvironment to inhibit cancer growth.
Key Takeaways
- Gilead agreed to pay $60m up front for rights to Compugen’s COM503 for solid tumors.
- The drug is only in preclinical development, but it could be a first-in-class method to release natural IL-18 in the tumor microenvironment to inhibit cancer growth
The companies announced the collaboration on 19 December, under which Gilead will pay $60m up front and another $30m in near-term milestone payments subject to the clearance of an investigational new drug (IND) application for COM503 by the US Food and Drug Administration, expected in 2024
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?